Global healthcare provider Zydus Cadila on Saturday said it received approval from the US Federal Drug Authority (USFDA) to market Amlodipine and Olmesartan Medoxomil tablets for the treatment of hypertension.
"The drug, meant for treating hypertension or to lower blood pressure with other anti-hypertensive agents, will be manufactured at our group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad," said the company in a regulatory filing to the BSE.
The company also received the federal regulatory approval on September 21 to market its Itraconazole capsules to treat fungal infections.
--IANS
fb/vd
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
